首页> 外文OA文献 >Mucosal Vaccination against Serogroup B Meningococci: Induction of Bactericidal Antibodies and Cellular Immunity following Intranasal Immunization with NadA of Neisseria meningitidis and Mutants of Escherichia coli Heat-Labile Enterotoxin
【2h】

Mucosal Vaccination against Serogroup B Meningococci: Induction of Bactericidal Antibodies and Cellular Immunity following Intranasal Immunization with NadA of Neisseria meningitidis and Mutants of Escherichia coli Heat-Labile Enterotoxin

机译:针对B群脑膜炎球菌的粘膜疫苗接种:脑膜炎奈瑟氏菌NadA和大肠杆菌热不稳定肠毒素突变体的鼻内免疫接种后,杀菌抗体和细胞免疫的诱导。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Conjugated polysaccharide vaccines protect against serogroup C meningococci. However, this approach cannot be applied to serogroup B, which is still a major cause of meningitis. We evaluated the immunogenicity of three surface-exposed proteins from serogroup B Neisseria meningitidis (App, NhhA, and NadA) identified during whole-genome sequencing. Mice were immunized intranasally with individual proteins in the presence of wild-type Escherichia coli heat-labile enterotoxin (LTwt), LTR72, a partially inactivated mutant, or LTK63, a completely nontoxic mutant, as the adjuvant. Each of the meningococcal proteins induced significant cellular responses; NhhA and NadA induced strong antibody responses, but only NadA induced bactericidal antibody when administered intranasally with mucosal adjuvants. In addition, immunoglobulin A and bactericidal antibodies were detected in the respiratory tract following intranasal delivery of NadA. Analysis of antigen-specific cytokine production by T cells from immunized mice revealed that intranasal immunization with NadA alone failed to generate detectable cellular immune responses. In contrast, LTK63, LTR72, and LTwt significantly augmented NadA-specific gamma interferon, interleukin-4 (IL-4), IL-5, and IL-10 production by spleen and lymph node cells, suggesting that both Th1 and Th2 cells were induced in vivo. The strongest cellular responses and highest bactericidal antibody titers were generated with LTR72 as the adjuvant. These findings demonstrate that the quality and magnitude of the immune responses generated by mucosal vaccines are influenced by the antigen as well as the adjuvant and suggest that nasal delivery of NadA with mucosal adjuvants has considerable potential in the development of a mucosal vaccine against serogroup B meningococci.
机译:共轭多糖疫苗可预防C群脑膜炎球菌。但是,这种方法不能应用于血清B组,血清B组仍然是脑膜炎的主要原因。我们评估了在全基因组测序中鉴定的血清群B脑膜炎奈瑟氏球菌(App,NhhA和NadA)的三种表面暴露蛋白的免疫原性。在野生型大肠杆菌不耐热肠毒素(LTwt),LTR72(一种部分灭活的突变体)或LTK63(一种完全无毒的突变体)作为佐剂的存在下,用个别蛋白对小鼠进行鼻内免疫。每个脑膜炎球菌蛋白都诱导明显的细胞反应。当与粘膜佐剂鼻内给药时,NhhA和NadA诱导强烈的抗体反应,但只有NadA诱导杀菌抗体。另外,鼻内递送NadA后在呼吸道中检测到免疫球蛋白A和杀菌抗体。对来自免疫小鼠的T细胞产生的抗原特异性细胞因子的分析表明,仅用NadA进行鼻内免疫无法产生可检测的细胞免疫应答。相反,LTK63,LTR72和LTwt显着增加了脾脏和淋巴结细胞产生的NadA特异性γ干扰素,白介素4(IL-4),IL-5和IL-10,这表明Th1和Th2细胞都是在体内诱导。以LTR72为佐剂产生最强的细胞反应和最高的杀菌抗体效价。这些发现表明,粘膜疫苗产生的免疫反应的质量和强度受抗原以及佐剂的影响,并表明与粘膜佐剂一起鼻腔输送NadA在开发针对血清B型脑膜炎球菌的粘膜疫苗方面具有巨大潜力。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号